Pfizer is advancing berobenatide (Phase 3) as its flagship obesity treatment, claiming efficacy comparable to tirzepatide and potentially superior to semaglutide. The company discontinued MET-224o, MET-097o, and the GIPR antagonist PF-07976016 after mid-phase trials failed to meet expectations. Berobenatide's monthly dosing and lower GI side effects position it competitively, though Pfizer's portfolio consolidation reflects challenges in crowded weight-loss drug development.